- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Valeant is selling its Australian unit iNova to raise $930 million to pay down debt.
Stocks significantly pared losses by the end of the session, though still ended slightly lower.